<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681938</url>
  </required_header>
  <id_info>
    <org_study_id>ALERT-IPC 2017-015</org_study_id>
    <nct_id>NCT03681938</nct_id>
  </id_info>
  <brief_title>Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?</brief_title>
  <official_title>Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission After 2 Cycles of Chemotherapy ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first
      remission remains controversial, in particular since the association of Rituximab with
      chemotherapy. Even though many randomized and non-randomized studies have been conducted,
      their is still no standard procedure . Recently, the use of early TEP (positron emission
      topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder
      patients who remain candidate to autograft in front-line. Nevertheless, in good-responder
      patients, the benefits of an intensification therapy ins term of long-lasting disease control
      remains discussion.

      This institutional retrospective study aims at comparing the outcome of early metabolic
      responder patients who received an intensification treatment to those who received a standard
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">July 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the survival without progress of transplanted patients versus not transplanted patients</measure>
    <time_frame>From the date of complete remission post C2 of chemotherapy up to 120 months</time_frame>
    <description>Medical follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Relapse Incidence</measure>
    <time_frame>From the date of complete remission post C2 of chemotherapy up to 120 months</time_frame>
    <description>Medical follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of complete remission post C2 of chemotherapy up to 120 months</time_frame>
    <description>Medical follow up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">183</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>Intensification treatment: Autograft</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chemotherapy (without autograft)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autograft</intervention_name>
    <description>Autograft</description>
    <arm_group_label>Intensification treatment: Autograft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With High Risk Big B Cells Lymphoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with High Risk Big B Cells Lymphoma

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Not applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BOUABDALLAH RÃ©da, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>Institut paoli-calmettes</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

